George Papakostas
Psychiatry · Boston, MANPI 1588654131
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (56.2%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 11 manufacturers reported payments, led by Boehringer Ingelheim International GmbH at 37.4% of the total. Reporting peaked in 2022 at $58,172 and has fallen 60.7% since, to $22,851 in 2025. Among psychiatry clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 101 payments — averaging $1686.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim International GmbH$64K
- Alkermes, Inc.$25K
- AbbVie$20K
- H. Lundbeck A S$19K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$9K
- Janssen Research & Development, LLC$9K
- plus $25K from 5 others
Across 4 payments — averaging $1375.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Otsuka Pharmaceutical Development & Commercialization, Inc.$6K
What the payments were for
- Consulting fees$95,68856%
- Speaking & faculty fees$14,8649%
- Travel & lodging$57,69734%
- Food & beverage$2,1231%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim International GmbH | 21 | $63,704 |
| Alkermes, Inc. | 1 | $24,800 |
| AbbVie | 31 | $20,331 |
| H. Lundbeck A S | 10 | $18,558 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 9 | $9,286 |
| Janssen Research & Development, LLC | 9 | $8,991 |
| Acadia Pharmaceuticals Inc | 2 | $8,000 |
| Livanova USA, Inc. | 6 | $7,081 |
| Boehringer Ingelheim | 8 | $6,239 |
| Alfasigma USA, Inc. | 3 | $3,338 |
| Otsuka America Pharmaceutical, Inc. | 1 | $44 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BRINTELLIX$13,331
- REXULTI$8,625
- NUPLAZID$8,000
- VNS Therapy Symmetry Model 8103 Generator$6,915
How this compares
$170,371 in reported general payments places this provider in the 95th percentile of 1,431 psychiatry providers in Massachusetts.
Other psychiatry in Boston
- Ximena Sanchez-SamperBoston$258K
- Maurizio FavaBoston$120K
- Andrew NierenbergBoston$94K
- Lee GoldsteinBoston$90K
- Gary SachsBoston$81K
- Dan IosifescuBoston$61K
- Lee CohenBoston$51K
- Michael OstacherBoston$39K
- Cristina MontalvoBoston$35K
- Roy PerlisBoston$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.